• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

    7/31/24 8:50:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email

    SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024.

    Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquisitions, litigation, regulatory and quality assurance, compliance, privacy, and government affairs.

    "Jennifer is a seasoned legal leader with a deep understanding of the biotech industry landscape and a remarkable ability to build cohesive teams," said Paul J. Diaz, President and CEO of Myriad Genetics. "Her industry experience and expertise, combined with her integrity, practical insight, and operational excellence, will be essential in guiding our legal strategy. We are immensely fortunate to welcome such a skilled legal expert to our executive team at Myriad Genetics."

    Fox most recently served as the Executive Vice President of External Affairs for Emergent BioSolutions where she was responsible for overseeing legal functions, government and public affairs, communications, and ESG initiatives. Prior to that role, she held positions with Brinks, Gilson & Lione, Novozymes North America and GSK. Fox holds a J.D. from North Carolina Central University, an M.S. in Biochemistry and Molecular Biology from the University of Toledo, and a B.S. in Biology, also from the University of Toledo.

    About Myriad Genetics

    Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that Fox will be essential in guiding the company's legal strategy. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

    Media Contact:

    Glenn Farrell

    (385) 318-3718

    [email protected]

    Investor Contact:

    Matt Scalo

    (801) 584-3532

    [email protected]

    To view Jennifer Fox: Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/89f4e64c-0023-4324-aada-018f70199e3f



    Primary Logo

    Get the next $MYGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    9/19/2024$32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

      SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients' individual risk. RiskScore, Myriad's clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer. The study, "Association of Polygenic

      5/7/25 4:30:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

      SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine. The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns. "It's encouraging to

      4/30/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

      SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. "Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric

      4/7/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Announces Senior Leadership Transition

      SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

      2/24/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $MYGN
    Financials

    Live finance-specific insights

    See more

    $MYGN
    SEC Filings

    See more
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon register

      4/29/25 9:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telep

      2/18/25 8:30:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Myriad Genetics Inc.

      10-Q - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 8:48:53 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 4:08:36 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Myriad Genetics Inc.

      S-8 - MYRIAD GENETICS INC (0000899923) (Filer)

      5/1/25 4:03:06 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Myriad Genetics downgraded by Wolfe Research

      Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

      5/8/25 8:27:12 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

      5/7/25 8:36:31 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Guggenheim

      Guggenheim downgraded Myriad Genetics from Buy to Neutral

      4/9/25 8:36:07 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

      SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

      11/14/24 4:16:31 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      5/1/24 4:21:33 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      4/25/24 4:18:40 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Commerical Officer Donnelly Brian J was granted 397,534 shares (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/2/25 4:15:16 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Donnelly Brian J

      3 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:29:48 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Verratti Mark

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:27:14 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care